Company intelligence / Profile preview

Kuria Therapeutics

Little Rock*, Arkansas, United Stateskuriatx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Kuria Therapeutics has demonstrated positive preclinical proof-of-concept data for its lead NRF2 activator in both cornea and other ophthalmic models. The company’s approach leverages the activation of the NRF2 pathway to protect and restore vision by addressing mitochondrial dysfunction and oxidative stress as root causes of blinding eye diseases. No clinical-stage results have been reported as of May 2025.

Therapeutic areas: OphthalmologyDermatology
Modalities: Small molecules (Nrf2 activators)Chemical drugs
Industry: Biotech

Drug pipeline

1 asset

KTX-1161

Pre-clinical

Indications: Fuchs' dystrophy, Corneal endothelial dysfunction

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of May 2025.

Beyond the preview

Go deeper on Kuria Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kuria Therapeutics.

Explore the full profile